Skip to main content
PolicySpeak
← All files
PAR

Psychedelic Access and Research European Alliance (PAREA)

NGO · Estonia · EU Transparency Register 163022446092-77

2
positions filed
in the 326 files tracked
1
legislative file
of 326 tracked
2
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 784 non-governmental organisations on this site, they rank #441 by legislative files engaged — a count of participation, not a measure of influence.

2.2
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2022
in the register since
Register category
Non-governmental organisations
Registered as
Psychedelic Access and Research European Alliance (PAREA)
Head office
Charneca de Caparica, Portugal

Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track Psychedelic in PolicySpeak: request access →

Work at Psychedelic Access and Research European Alliance (PAREA)? so we know who speaks for it.

Follow the file Psychedelic Access and Research European Alliance (PAREA) engages with

One email on Tuesdays when a new position is filed on this file, from Psychedelic Access and Research European Alliance (PAREA) or from anyone else on it. Only when there is something new.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Their record over time

Psychedelic Access and Research European Alliance (PAREA) filed 2 positions between 6 Jun 2025 and 25 May 2026, across 1 of the 326 legislative files tracked here, attaching a full position paper 2 times.

2025 · 1 filed2026 · 1 filed

What they argued

European Biotech Actfiled 25 May 2026PDFsource

PAREA welcomes the development of a European Biotech Act and strongly supports its goals. However, the initiative should explicitly address one of the clearest examples of market and regulatory failure in European health innovation: mental health. Mental health conditions represent one of the largest and most persistent unmet needs in Europe.

European Biotech Actfiled 6 Jun 2025PDFsource

PAREA welcomes the Commissions ambition to strengthen the European biotech ecosystem. The Biotech Act can play a crucial role in unlocking innovation in areas that combine high public health need with persistent underinvestment - notably mental health. Mental health is not just another disease area. It is a foundational layer that cuts across all aspects of human life and societal functioning.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Is this your organization?

Everything on this page comes from Psychedelic Access and Research European Alliance (PAREA)’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.